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Elisabeth Aavall-Lundqvist6, Ignace Vergote7, Per Rosenberg8, Karin Boman9 and Britta Nordstrøm10Abstract
Background: We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with
advanced, persistent or recurrent endometrial carcinoma.
Methods: We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51
patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer. Patients were stratified into
subsets of estrogen receptor (ER) positive and ER negative patients.
Results: Recruitment to the ER negative group was stopped prematurely after 12 patients due to slow accrual. In
the ER positive patients, we observed an overall response rate of 10%, and a lack of progression after 6 months in
35% of the patients. No responses were registered in the ER negative patients, and all had progressive disease
within 6 months. For the total group of patients, the median progression free survival (PFS) was 3.1 months
(95% CI: 2.0-4.1). In the ER positive patients the median PFS was 3.8 months (95% CI: 0.7-6.9) and in the ER negative
patients it was 2.6 months (95% CI: 2.1-3-1). In the ER positive patients the median overall survival (OS) time was
13.3 months (95% CI: 7.7-18.9), in the ER negative patients the corresponding numbers were 6.1 months (95% CI:
4.1-8.2). Treatment with exemestane was well tolerated.
Conclusion: Treatment of estrogen positive advanced or recurrent endometrial cancer with exemestane, an
aromatase inhibitor, resulted in a response rate of 10% and lack of progression after 6 months in 35% of the
patients.
Trial registration: Trial identification number (Clinical Trials.gov): NCT01965080.
Nordic Society of Gynecological Oncology: NSGO–EC–0302.
EudraCT number: 2004-001103-35.
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Endometrial cancer is the most common cancer of the
female genital tract in many Western countries, and
some of the highest incidence rates have been observed
in European populations [1]. Long-term predictions im-
ply that the burden of endometrial cancer will continue* Correspondence: gunnar.b.kristensen@gmail.com
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article, unless otherwise stated.to increase in the forthcoming decades owing not only
to the aging population but also to the obesity epidemic
[2]. The majority of patients are diagnosed at an early
stage with favourable prognosis. However, a considerable
proportion of patients continue to present with locally
advanced or recurrent disease.
There are two distinct endometrial tumour types, type
I and type II endometrial cancer. They differ in pathoge-
nesis, histology and prognosis. Type I tumours are often
well differentiated and characterized by endometrioid hist-
ology. These tumours are hormone dependent but clinical
data on the expression of hormone receptors is scarce. Atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in two-third of the tumors [3]. Hormone therapy is a par-
ticularly attractive option for the treatment of advanced
endometrial cancer because it is well tolerated and lacks
the usual toxicities associated with chemotherapy. Accu-
mulated experience with a variety of hormonal regimens
suggests that between 15 and 30 percent of women re-
spond to hormone therapy [4], with a correlation between
receptor status and response to hormone therapy [5,6].
However, metastatic or recurrent disease may be different
from primary disease as regards tumour biology and re-
ceptor status [7], and a recent Cochrane review found no
evidence that hormonal treatment in any form improves
survival in this patient group [8].
In postmenopausal women or after oophorectomy, the
major source of circulating estrogen is conversion of ad-
renal androstenedione to estron by aromatase activity in
adipose tissue with further conversion to estradiol [9]. In
the first line treatment of postmenopausal women with
hormone receptor-positive breast cancer, aromatase in-
hibitors (AI’s) have shown superior efficacy as compared
with tamoxifen. However, there is very little clinical evi-
dence on the efficacy of AI’s in endometrial cancer. Pre-
vious studies of the AI’s letrozole and anastrozole have
only shown limited effect [10,11]. Exemestane is an oral
irreversible steroidal AI and has been shown to decrease
circulating estrogens in postmenopausal women [12].
Exemestane is given as an oral dose once daily and
may therefore be a convenient drug in the treatment
of advanced endometrial cancer. We present the final
results of an open-label phase II study on the efficacy
and safety of the aromatase inhibitor exemestane in the
treatment of patients with advanced, persistent or re-
current endometrial carcinoma of endometrioid type.
Preliminary results were previously presented at the
2006 Annual Meeting of the American Society of Clinical
Oncology [13].
Methods
Study design
This open-label phase II study was designed to evaluate
the efficacy and safety of exemestane in the treatment of
patients with advanced, persistent or recurrent endomet-
rial carcinoma of endometrioid type.
The study was designed and carried out in accordance
with good clinical practice, the declaration of Helsinki
and national laws. The local ethics committee at each
participating center approved the study (Belgia: Com-
missie Medische Ethiek van Universitaire Ziekenhuizen
KU Leuven; Danmark: Den Videnskabsetiske komite or
Vejle og Fyns Amter; Norway: Regional Committees For
Medical and Health Research Studies; Sweden: Regional
ethical review board). All patients gave their written in-
formed consent before study entry.Patients received 25mg of oral exemestane once daily,
preferable after a meal, on an outpatient basis.
Eligibility criteria, randomization, and quality assurance
Patients with histologically confirmed advanced (FIGO
stage III-IV) or relapsed endometrial cancer of endome-
trioid type not considered for curative treatment were
eligible. Patients could have been treated by surgery,
radiotherapy and/or chemotherapy. All patients had to
have at least one measurable lesion located outside the
previously irradiated area. Lesions located within irradi-
ated area were considered as non-target lesions. Relapse
was verified by cytology or histology. Time from any can-
cer treatment had to be at least 1 month. Patients were
included irrespective of hormone receptor status. Only
postmenopausal women with a WHO performance status
of 0-2 were included. Adequate renal and hepatic func-
tion, defined as follows, was required: ASAT or ALAT of
no more than 4 x upper normal limit (UNL) and serum
creatinine <150 mmol/L. Exclusion criteria were: Patients
with symptomatic brain metastases, a history of other pri-
mary malignancies except for carcinoma in situ of the cer-
vix and basal cell carcinoma of the skin, a history of
thromboembolic disease, congestive heart failure (NYHA
classification >2) or any treatment that might interact with
the study drug (i.e., carbamazine or cyclosporine).
The Nordic Society of Gynecologic Oncology (NSGO)
data center checked all of the data collected on case re-
port forms for consistency.
Pathological review and immunohistochemical staining
Pathological review of the tumors was conducted on an
institutional basis by pathologists well trained in gyne-
cological pathology. Estrogen receptor (ER) staining was
considered positive if nuclear staining in more than 10%
of the tumor cells was 2+ or higher.
Evaluations and follow-up
During the treatment period patients were seen every
three months during the first year, every six months du-
ring the second year and thereafter until disease prog-
ression. Each clinical visit included laboratory tests (full
blood cell count, serum creatinine, ASAT/ALAT), a phy-
sical examination, assessment of performance status and
adverse events and tumor evaluation with computed tom-
ography. Response was defined according to the RECIST
criteria [14]. For evaluation of response rate, patients had
to have at least one tumor assessment performed after
start of therapy. For categorization as stable disease the
disease had to have been stable for at least 6 months.
Adverse events and toxicity were graded by the study
investigators according to the National Institute Common
Toxicity Scale version 2.0 [15]. Toxicities were recorded
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whole treatment period for each patient.
Statistical analyses
The primary endpoint measure was objective response
rate. Secondary endpoints were toxicity, progression free
(PFS) and overall (OS) survival. The response rate and
survival endpoints were evaluated in each of two separ-
ate subsets: A) ER positive and B) ER negative tumors.
In each subset the SWOG 2 stage design [16] was used
with a targeted response rate of 30% and a rate of only
10% as unacceptable low. An accrual of 20 in the first
stage (stage 1) and 15 in the second stage (stage 2) for
each subset was targeted, resulting in approximate sig-
nificance level and power of 0.05 and 0.9 respectively. In
case of less than 2 responses observed in the first stage
of the study, the respective subset would be closed. With
2 or more responses, the subset would continue to the
second stage.
Objective response rate was evaluated based on the
total number of evaluable patients in the subset. Pro-
gression free survival was defined as the time from study
entry to disease progression or death of any cause. Pa-
tients still alive with no progression were censored at
the date of their last follow-up visit. Overall survival was
defined as the time from study entry to death of any
cause. Patients still alive were censored at the date of
their last follow-up visit. Survival was analyzed using the
Kaplan-Meier method. Efficacy analyses were performed
on all randomly assigned patients on an intention-to-
treat basis. All patients were evaluable for safety analysis
from the time of their first dose of treatment. The
STRATA statistical package, version 10.0, was used for
the analysis.Figure 1 Enrollment, randomization and treatment response.Results
Patients and follow-up
Between 01.03.2004 and 30.11.2006, 62 patients were
screened for this trail, of which 52 fulfilled all eligibility
criteria and were enrolled (Figure 1). After accrual of
12 patients with ER negative tumors who all progressed
shortly, investigators stopped recruitment to this group.
Thirty-four (65.4%) patients with relapse were included.
Ten patients suffered from relapse after surgery alone,
8 of whom presented with disease outside the pelvis.
Disease was primarily metastatic in 18 (34.6%) patients.
Description of treatment given prior to inclusion in
the study is given in Table 1. All patients but four
had undergone surgery with hysterectomy and bilateral
salpingo-oophorectomy. These four patients with pri-
marily metastatic disease had a diagnostic curettage be-
fore treatment with radiation and/or chemotherapy.
Treatment compliance and toxicity
Exemestane was well tolerated in this study. The re-
ported incidence of non-hematological toxicity is shown
in Table 2. Most of the events were of grade 1 or 2.
Grade 3-4 anorexia was reported by 2 patients (3.8%).
There were 3 cases (5.8%) of venous thrombosis. The re-
ported hematological toxicity is shown in Table 3. Grade
3-4 anemia was reported in 28 (53.8%) of the patients.
Tumor response and survival
One patient with ER negative tumor stopped treatment
after 3 weeks owing to deteriorated performance status
and clinical signs of progression but without radiologic
evaluation. Objective evaluation of response according
to RECIST was done in 51 patients. During treatment and
follow-up, a total of 43 patients had disease progression
Table 1 Baseline patient characteristics
Characteristic ER positive ER negative Total
No. of patients % No. of patients % No. of patients %
No. of patients 40 76.9 12 23.1 52 100
Age, years
Range 42.9–82.8 59.4–82.5 42.9–82.8
Median 70.0 67.7 69.5
FIGO stage* 52 100
I 13 32.5 9 75.0 22 42.3
II 6 15.0 1 8.3 7 13–5
III 11 27.5 2 16.7 13 25.0
IV 10 25.0 0 0 10 19.2
Grade 52 100
Well differentiated 7 17.5 0 0 7 13.5
Mod. differentiated 17 42.5 7 58.3 24 46.2
Poorly differentiated 14 35.0 5 41.7 19 36.5
Not specified 2 5.0 0 0 2 3.8
Disease status at inclusion 52 100
Relapse 26 65 8 66.7 34 65.4
Primary metastatic disease 14 35 4 33.3 18 34.6
Previous treatment 52 100
Surgery alone 11 27.5 1 8.3 12 23.1
Surgery and radiation 8 20.0 1 8.3 9 17.3
Surgery and chemotherapy 7 17.5 3 25.0 10 19.2
Surgery, radiation and chemotherapy 14 35.0 7 58.3 21 40.4
*Stage at primary diagnosis.
Table 2 Non-hematologic toxicity by toxicity grade
(NCI-CTC)
Toxicity 1 2 3 4
No. % No. % No. % No. %
Anorexia 8 15.4 5 9.6 1 1.9 1 1.9
Nausea 11 21.2 2 3.8 1 1.9 0 0
Vomiting 5 9.6 1 1.9 1 1.9 0 0
Abdominal pain 4 7.7 4 7.7 1 1.9 0 0
Hot flushes 6 11.5 3 5.8 0 0 0 0
Sweating 7 13.5 4 7.7 0 0 0 0
Fatigue 9 17.3 9 17.3 2 3.8 0 0
Dizziness 5 9.6 1 1.9 1 1.9 0 0
Headache 4 7.7 2 3.8 0 0 0 0
Weight gain 4 7.7 1 1.9 0 0 0 0
Insomnia 5 9.6 4 7.7 0 0 0 0
Edema 3 5.8 1 1.9 0 0 0 0
Venous thrombosis 0 0 0 0 3 5.8 0 0
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died from intercurrent disease (intracranial bleeding),
while in complete remission (CR) for 23 months. At the
end of follow-up one patient was in CR with PFS of 55.3
months, 2 had partial remission (PR) with PFS of 26.6 and
25.6 months, respectively. Four patients had stable disease
(SD) with PFS of 40.7, 9.6, 7.9 and 10.9 months, respec-
tively. Twelve patients with ER negative tumors were re-
gistered. In the 11 ER negative patients evaluable for
response, no response was observed. The trial was stopped
prematurely in the ER negative group due to lack of re-
cruitment. In the ER positive group the trial advanced into
stage 2 and a total of 40 patients were recruited. The re-
sponse status after 6 months of treatment was: Progressive
disease in 26 patients, complete response in 2, partialTable 3 Hematologic toxicity by toxicity grade (NCI-CTC)
Toxicity 1 2 3 4
No. % No. % No. % No. %
WBC/granulocytes 2 3.8 0 0 0 0 0 0
Platelets 0 0 0 0 1 1.9 0 0
Hemoglobin 7 13.5 2 3.8 1 1.9 27 51.9
Figure 3 Overall survival according to receptor status.
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gives an overall response rate of 10% and absence of
progression in 14 patients (35%).
For the total group of patients, the median progression
free survival was 3.1 months (95% CI: 2.0-4.1). In the
group of ER positive patients the median progression
free survival was 3.8 months (95% CI: 0.7-6.9). Progres-
sion free survival was 2.6 months (95% CI: 2.1-3.1) in
the group of ER negative patients (Figure 2). At the end
of the study, 7 patients in the ER positive group were
progression free.
During follow-up 38 patients (73.1%) died. For the
total group of patients, the median overall survival time
was 10.9 months (95% CI: 3.4-18.0). In the group of ER
positive patients the median overall survival time was
13.3 months (95% CI: 7.8-18.9). ER negative patients
survived for a median of 6.1 months (95% CI: 4.1-8.2)
(Figure 3).
Discussion
The treatment with exemestane was generally well tole-
tated. The response rate in the ER positive group was
10%. In the design of the study, a response rate of 10%
or less was considered as of no clinical interest. In retro-
spect, the use of response rate as endpoint for this study
can be questioned. Long term stabilization, such as lack
of progression at 6 months may be a more relevant end-
point. We observed a lack of progression in 35% of pa-
tients at 6 months, which seems of clinical interest.
Tumors are heterogeneous, and the definition used for
ER positivity in this study was 2+ or more in staining in-
tensity for at least 10% of tumor cells. This means that a
substantial proportion of the tumor cells may have
stained negative for ER in a number of tumors included
in the ER positive group. The tumor cells that stained
negative for ER in the ER positive patient group may not
have responded to the treatment, and the progressions
in this group may be attributable to these tumor cells.Figure 2 Progression free survival according to receptor status.Patients with long-term response or stabilization of the
disease may show more uniform ER positivity of the
tumor cells but unfortunately the degree of staining was
not specified in the study. We were therefore not able to
validate this hypothesis.
Recruitment in the ER negative subset was stopped
prematurely after recruitment of 12 patients because of
lack of response and rapid progression in these patients.
We cannot conclude too strongly about this subset due
to the small number of patients, but do consider the re-
sults as disappointing.
There are other weaknesses in this study. Pathological
review and histological staining of the tumors were per-
formed on an institutional basis. However, all institutions
were university hospitals with well-trained gynecological
pathologists. Immunostaining of estrogen receptor is well
established, and there is broad consensus about evaluation
of staining results. In 24 cases (46.1%), receptor status was
evaluated in the primary tumor only. However, expression
of hormone receptors may change during progression of
the disease and receptor status of metastatic disease may
not always correspond to the receptor expression of the
primary tumor. The trial was designed as a single-arm
phase II study and hence did not include a control arm.
Therefore we cannot exclude the lower progression rate
observed in the ER positive group being attributable to a
difference in tumor biology not related to the ER receptor
status.
Two previous studies of the aromatase inhibitors letro-
zole and anastrozole in endometrial cancer patients have
reported disappointing results. Ma et al. reported a re-
sponse rate of 9% in 32 patients in abstract form [10].
There was no significant correlation with hormone re-
ceptor status, but data on receptor status was available
in only one third of the patients. Another phase II trial
of anastrozole observed only two partial responses in 23
patients. They reported ER and PR positivity in 21.7%
of the patients and patients enrolled in the study were
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In a recent abstract report on 42 patients with recur-
rent endometrial cancer, the effects of concomitant
letrozole and the mTOR inhibitor everolimus were stu-
died [16]. The response rate was 20% and the 12 month
progression-free rate was 37%. The previously reported
low response rates of endocrine therapy in endometrial
cancer, especially with AI’s, may reflect the need to iden-
tify the subset of women most likely to respond to such
therapy. In our study we therefore selected type I endo-
metrial cancers, and 77% of the tumors in our study popu-
lation were ER positive. In this subgroup, we report a
response rate of 10%. The lack of progression within 6
months in 35% of the patients is of clinical interest and
may warrant further evaluation in this group of patients.
In receptor negative patient, no responses were observed,
and patients progressed quickly. In this subgroup, further
evaluation of this kind of treatment seems of less interest.
In order to evaluate the potential benefit of endocrine
treatment, hormone receptor status should always be eval-
uated, preferably in the metastatic sites, but at least in the
primary tumor.Conclusions
Treatment of estrogen positive advanced or recurrent
endometrial cancer with exemestane, an aromatase inhi-
bitor, resulted in a response rate of 10% and a lack of pro-
gression at 6 months of treatment in 35% of patients with
ER positive tumors. The treatment was well tolerated.
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